Looking Beyond the Lower Airways: COPD and Coexisting Allergic Rhinitis
25 Aug 2026
Respiratory symptom burden does not always stop at the lower
airways. In patients with chronic obstructive pulmonary disease (COPD),
persistent nasal symptoms may coexist with breathlessness, cough and activity
limitation, adding another layer to disease burden. Recognizing symptoms
arising from both the upper and lower airways may therefore support a more
complete and individualized approach to respiratory care.
A 2024 literature review found that chronic nasal symptoms were reported in up to 88% of patients with COPD across the included studies, with rhinorrhea identified as the most frequently reported symptom. The review also found associations between chronic rhinitis and poorer quality of life, higher COPD symptom scores, exacerbations and hospitalization. In one study, patients with allergic rhinitis had a 2.4-fold higher risk of 30-day COPD-related readmission than patients without rhinitis. These findings do not establish that rhinitis causes poorer COPD outcomes, but they support actively evaluating persistent nasal symptoms rather than viewing COPD exclusively as a lower-airway disease.1
For COPD, treatment should remain aligned with guideline-directed management. The 2025 GOLD report identifies long-acting bronchodilation as a central component of maintenance therapy, selected according to symptom burden and exacerbation risk.2 Tiotropium bromide is a once-daily long-acting muscarinic antagonist (LAMA) that provides sustained bronchodilation when LAMA therapy is appropriate.3
A network meta-analysis of 24 randomized trials compared tiotropium with the newer LAMAs (aclidinium, glycopyrronium, and umeclidinium). Tiotropium improved trough FEV1 versus placebo by 114.1 mL at 12 weeks and 106.4 mL at 24 weeks. The newer agents demonstrated at least comparable efficacy to tiotropium, which the authors described as the established class standard.3 A 2022 systematic review and meta-analysis of 33 studies further found that LAMA therapy reduced COPD exacerbations and improved lung function, dyspnea, and health-related quality of life versus placebo.4 Together, these findings support that tiotropium remains a well-established option within the LAMA class.
When assessment confirms concomitant allergic rhinitis, treatment should address upper-airway symptoms through an appropriate, disease-specific approach. Levocetirizine blocks histamine-mediated responses, while montelukast inhibits cysteinyl leukotriene signaling, providing complementary mechanisms of action.5
In a meta-analysis of seven randomized trials involving 887 patients, levocetirizine plus montelukast produced greater improvements in rhinorrhea (standard mean difference [SMD], −0.69; 95% CI, −1.09 to −0.30) and nasal congestion (SMD, −0.64; 95% CI, −1.05 to −0.24) compared with monotherapy. Improvements were also observed in sneezing, nasal itching, and overall daytime and nighttime symptoms, without a significant increase in treatment-emergent adverse events.5
COPD and allergic rhinitis remain distinct conditions requiring condition-specific treatment. Looking beyond the lower airways, however, may help clinicians recognize coexisting symptoms and address the broader respiratory burden experienced by each patient.
A 2024 literature review found that chronic nasal symptoms were reported in up to 88% of patients with COPD across the included studies, with rhinorrhea identified as the most frequently reported symptom. The review also found associations between chronic rhinitis and poorer quality of life, higher COPD symptom scores, exacerbations and hospitalization. In one study, patients with allergic rhinitis had a 2.4-fold higher risk of 30-day COPD-related readmission than patients without rhinitis. These findings do not establish that rhinitis causes poorer COPD outcomes, but they support actively evaluating persistent nasal symptoms rather than viewing COPD exclusively as a lower-airway disease.1
For COPD, treatment should remain aligned with guideline-directed management. The 2025 GOLD report identifies long-acting bronchodilation as a central component of maintenance therapy, selected according to symptom burden and exacerbation risk.2 Tiotropium bromide is a once-daily long-acting muscarinic antagonist (LAMA) that provides sustained bronchodilation when LAMA therapy is appropriate.3
A network meta-analysis of 24 randomized trials compared tiotropium with the newer LAMAs (aclidinium, glycopyrronium, and umeclidinium). Tiotropium improved trough FEV1 versus placebo by 114.1 mL at 12 weeks and 106.4 mL at 24 weeks. The newer agents demonstrated at least comparable efficacy to tiotropium, which the authors described as the established class standard.3 A 2022 systematic review and meta-analysis of 33 studies further found that LAMA therapy reduced COPD exacerbations and improved lung function, dyspnea, and health-related quality of life versus placebo.4 Together, these findings support that tiotropium remains a well-established option within the LAMA class.
When assessment confirms concomitant allergic rhinitis, treatment should address upper-airway symptoms through an appropriate, disease-specific approach. Levocetirizine blocks histamine-mediated responses, while montelukast inhibits cysteinyl leukotriene signaling, providing complementary mechanisms of action.5
In a meta-analysis of seven randomized trials involving 887 patients, levocetirizine plus montelukast produced greater improvements in rhinorrhea (standard mean difference [SMD], −0.69; 95% CI, −1.09 to −0.30) and nasal congestion (SMD, −0.64; 95% CI, −1.05 to −0.24) compared with monotherapy. Improvements were also observed in sneezing, nasal itching, and overall daytime and nighttime symptoms, without a significant increase in treatment-emergent adverse events.5
COPD and allergic rhinitis remain distinct conditions requiring condition-specific treatment. Looking beyond the lower airways, however, may help clinicians recognize coexisting symptoms and address the broader respiratory burden experienced by each patient.